MY148542A - A method for the assessment of cancer in a biological sample obtained from a subject - Google Patents

A method for the assessment of cancer in a biological sample obtained from a subject

Info

Publication number
MY148542A
MY148542A MYPI20092453A MY148542A MY 148542 A MY148542 A MY 148542A MY PI20092453 A MYPI20092453 A MY PI20092453A MY 148542 A MY148542 A MY 148542A
Authority
MY
Malaysia
Prior art keywords
cancer
assessment
present
subject
biological sample
Prior art date
Application number
Inventor
Teo Soo Hwang
Yap Lee Fah
Muhammad Mamduh Ahmad Zabidi
Original Assignee
Cancer Res Initiatives Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Initiatives Foundation filed Critical Cancer Res Initiatives Foundation
Priority to MYPI20092453 priority Critical patent/MY148542A/en
Priority to SG2011090008A priority patent/SG176683A1/en
Priority to CN2010800267968A priority patent/CN102498219A/en
Priority to PCT/MY2010/000097 priority patent/WO2010147452A1/en
Publication of MY148542A publication Critical patent/MY148542A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

THE PRESENT INVENTION RELATES TO A METHOD FOR AIDING IN THE ASSESSMENT AND DIAGNOSIS OF CANCER BY DETERMINING THE EXPRESSION LEVEL OF GENE FOUR-JOINTED BOX 1 (FJX1). THE METHOD OF THE PRESENT INVENTION MAY BE USED FOR AIDING IN THE ASSESSMENT OF CANCER IN PARTICULAR NASOPHARYNGEAL CARCINOMA (NPC). THE PRESENT INVENTION ALSO RELATES TO POLYPEPTIDES, ANTIBODIES AND NUCLEIC ACIDS FOR THE USE IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING CANCER AND A KIT FOR PERFORMING THE METHOD OF THE PRESENT INVENTION.
MYPI20092453 2009-06-15 2009-06-15 A method for the assessment of cancer in a biological sample obtained from a subject MY148542A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MYPI20092453 MY148542A (en) 2009-06-15 2009-06-15 A method for the assessment of cancer in a biological sample obtained from a subject
SG2011090008A SG176683A1 (en) 2009-06-15 2010-06-10 A method for the assessment of cancer in a biological sample obtained from a subject
CN2010800267968A CN102498219A (en) 2009-06-15 2010-06-10 A method for the assessment of cancer in a biological sample obtained from a subject
PCT/MY2010/000097 WO2010147452A1 (en) 2009-06-15 2010-06-10 A method for the assessment of cancer in a biological sample obtained from a subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20092453 MY148542A (en) 2009-06-15 2009-06-15 A method for the assessment of cancer in a biological sample obtained from a subject

Publications (1)

Publication Number Publication Date
MY148542A true MY148542A (en) 2013-04-30

Family

ID=43858437

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20092453 MY148542A (en) 2009-06-15 2009-06-15 A method for the assessment of cancer in a biological sample obtained from a subject

Country Status (4)

Country Link
CN (1) CN102498219A (en)
MY (1) MY148542A (en)
SG (1) SG176683A1 (en)
WO (1) WO2010147452A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658816A (en) * 2013-10-04 2016-06-08 世程发展公司 Methods and devices for nasopharyngeal carcinoma screening
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
KR20230162145A (en) * 2017-06-23 2023-11-28 아네트 웨이어강 Diagnosis and treatment of cancer
CN110534156B (en) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 Method and system for extracting immunotherapy new antigen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CN1854313B (en) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 Method for diagnosing non-small cell lung cancers
US8153368B2 (en) * 2007-06-25 2012-04-10 Vanderbilt University Four-jointed box (FJX1) in cancer diagnosis and treatment

Also Published As

Publication number Publication date
CN102498219A (en) 2012-06-13
WO2010147452A8 (en) 2012-01-05
WO2010147452A1 (en) 2010-12-23
SG176683A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2010091049A3 (en) Diagnosis and treatment of cancer
IN2012DN00866A (en)
MX368513B (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis.
MX2010000537A (en) Monoclonal antibodies against glypican-3.
MX2021000210A (en) Methods and products for transfecting cells.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
MX2012004084A (en) Siglec 15 antibodies in treating bone loss-related disease.
ATE533838T1 (en) METHOD FOR IMPROVED INTRODUCTION OF DNA INTO BACTERIAL CELLS
MX2010008096A (en) Ferroportin antibodies and methods of use.
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
EP2576837A4 (en) Prostate cancer associated circulating nucleic acid biomarkers
TW200626900A (en) Wnt proteins and detection and treatment of cancer
CL2007003649A1 (en) An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70.
GB201020995D0 (en) Biological materials and uses thereof
GB2459228A (en) Exosome-associated microrna as a diagnostic marker
WO2012045905A3 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
DE602007003331D1 (en) PROCESS FOR DETERMINING THE COPY NUMBER
EP3009454A3 (en) Antibodies specific to cadherin-17
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
PL2021794T3 (en) Use of protein s100a 12 as a marker for colorectal cancer
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk